ovarian cancer Tag

30 Apr

Posted at 15:35h in General Medicine
MedicalResearch.com: Egle Avizienyte, PhD Senior Research Fellow, Institute of Cancer Sciences Faculty of Medical and Human Sciences The University of Manchester, Manchester M20 4BX MedicalResearch.com: What are the main findings of the study? Dr. Avizienyte: Angiogenesis, the formation of new blood vessels, has been validated as a target in ovarian cancer. However, the benefit from anti-angiogenic therapies, e.g. Vascular Endothelial Growth Factor (VEGF) pathway inhibitors that are currently used in the clinic for the treatment of ovarian cancer has been modest, largely because of redundancy in angiogenic cytokines that regulate tumour angiogenesis. In this study we validated heparan sulphate 6-O-sulfotranferases 1 and 2 (HS6ST-1 and -2) as targets for developing new therapeutic anti-angiogenic agents for the treatment of ovarian cancer. The data generated in our laboratory show that HS6STs induce the angiogenic programme in ovarian cancer cells and has a major effect on tumour angiogenesis.

08 Oct

Posted at 01:02h in Cancer Research, Heart Disease, MD Anderson, Ovarian Cancer
Anil K. Sood MD Department of Gynecologic Oncology The University of Texas MD Anderson Cancer Center Unit 1362, PO Box 301439, Houston, TX, 77030MedicalResearch.com Interview with: Anil K. Sood MD Department of Gynecologic Oncology The University of Texas MD Anderson Cancer Center Unit 1362, PO Box 301439, Houston, TX, 77030 MedicalResearch.com: What are the main findings of the study? Dr. Sood: For women with newly diagnosed ovarian cancer, high heart rate at diagnosis (tachycardia), venous thromboembolism (VTE) occurring after diagnosis and pulmonary hypertension post-diagnosis are independently related to reduced survival after controlling for tumor stage, grade, and extent of cytoreduction.  Women with tachycardia lived an average of 4.0 years after diagnosis compared with 5.9 years for women without tachycardia, a 32% reduction in duration of survival.  Patients who experienced VTE lived a median 4.1 years after diagnosis, compared with 6.4 yrs for patients who did not experience VTE.

16 Aug

Posted at 18:25h in Biomarkers, Cancer Research
MedicalResearch.com Interview with: Martin Köbel M.D. Assistant Professor, Pathology and Lab Medicine
Calgary Laboratory Services 9 3535 Research Road Nw Calgary, Alberta T2L 2K8 Canada MedicalResearch.com: What are the main findings of the study? Answer:  Ovarian carcinomas are now divided into five histological types, which differ with respect to biology and clinical behaviour. However, the histological type assessment varies from center to center. Our study emphasizes the need for a standardized method to identify them. Until such consistent approach is established, histological types from various centers may not comprise the same entities and studies will give inconsistent results.

26 Oct

Posted at 20:27h in Ovarian Cancer

October 25 2011 More patients with ovarian carcinoma carry cancer-predisposing mutations, and in more genes, than previously thought. A rapid experimental method for screening genomes has located mutations in 12 genes for inherited cancers of the ovary, fallopian tubes and peritoneum (the thin tissue lining the lower abdomen). More than one-fifth of ovarian...

19 Sep

Posted at 20:19h in Ovarian Cancer

Ovarian cancer is one of the most frequent forms of cancer that affect women. As tumors can initially grow unchecked in the abdomen without causing any major symptoms, patients are usually diagnosed at an advanced stage and have to undergo surgery plus chemotherapy. During the operation, surgeons attempt to remove...